KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Abbott Laboratories (ABT) Tax Provisions (2016 - 2026)

Abbott Laboratories' Tax Provisions history spans 18 years, with the latest figure at $372.0 million for Q1 2026.

  • On a quarterly basis, Tax Provisions fell 17.88% to $372.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.9 billion, a 130.27% increase, with the full-year FY2025 number at $1.9 billion, up 130.4% from a year prior.
  • Tax Provisions hit $372.0 million in Q1 2026 for Abbott Laboratories, down from $582.0 million in the prior quarter.
  • Over the last five years, Tax Provisions for ABT hit a ceiling of $582.0 million in Q4 2025 and a floor of -$7.2 billion in Q4 2024.
  • Historically, Tax Provisions has averaged -$103.6 million across 5 years, with a median of $305.0 million in 2024.
  • Biggest five-year swings in Tax Provisions: tumbled 3681.59% in 2024 and later soared 114.69% in 2025.
  • Tracing ABT's Tax Provisions over 5 years: stood at $287.0 million in 2022, then fell by 29.97% to $201.0 million in 2023, then tumbled by 3681.59% to -$7.2 billion in 2024, then soared by 108.08% to $582.0 million in 2025, then crashed by 36.08% to $372.0 million in 2026.
  • Business Quant data shows Tax Provisions for ABT at $372.0 million in Q1 2026, $582.0 million in Q4 2025, and $536.0 million in Q3 2025.